<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The histological diagnosis of non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> excluded) in 147 children was reviewed </plain></SENT>
<SENT sid="1" pm="."><plain>The most common site of presentation was in the abdomen (32.6%) </plain></SENT>
<SENT sid="2" pm="."><plain>The most frequent site of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> at diagnosis was the bone marrow (27.2%) </plain></SENT>
<SENT sid="3" pm="."><plain>The most common histology was diffuse undifferentiated non-Burkitt type (37.4%) </plain></SENT>
<SENT sid="4" pm="."><plain>According to the Murphy staging system, 40.1% were stage III and 27.2% were stage IV </plain></SENT>
<SENT sid="5" pm="."><plain>In a nonrandomized prospective study, 121 patients were submitted to a treatment regimen (protocol 8001) and compared with 26 historical controls treated with the COP regimen, consisting of <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi>, <z:chebi fb="0" ids="28445">vincristine</z:chebi>, and <z:chebi fb="0" ids="8382">prednisone</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Of those patients treated with protocol 8001, nine had intestinal <z:mpath ids='MPATH_81'>perforation</z:mpath> at the site of <z:e sem="disease" ids="C0277554" disease_type="Disease or Syndrome" abbrv="">primary disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients in this group were malnourished at the time of <z:mpath ids='MPATH_81'>perforation</z:mpath> </plain></SENT>
<SENT sid="8" pm="."><plain>The overall rate of initial complete remission in those patients treated with protocol 8001 was 90.7% </plain></SENT>
<SENT sid="9" pm="."><plain>The duration of remission was from 16 to 108 months, with a median of 39 months </plain></SENT>
<SENT sid="10" pm="."><plain>The actuarial rate of disease-free survival was 69% at 2 years and 63% at 6 years, compared with 36% at 6 years of the control group (COP) (p less than 0.01) </plain></SENT>
<SENT sid="11" pm="."><plain>None of the patients have relapsed after 4 years </plain></SENT>
</text></document>